Aspira Women’s Health, a bio-analytical women’s health company focused on gynecologic disease diagnostics, has entered into a new laboratory services agreement with the University of Texas Medical Branch at Galveston (UTMB Galveston), part of the University of Texas System.
The 12-month contract represents a key milestone in Aspira’s redefined marketing strategy, which targets large healthcare organizations capable of efficiently introducing the company’s solutions to thousands of potential patients and providers through each new institutional partnership. The collaboration will expand access to Aspira’s Ova1Plus and OvaWatch diagnostic products in the Texas market, enhancing early detection and management of ovarian disease.
Aspira has positioned this new contract as a critical step in scaling its platform and advancing its mission to improve women’s health through precision diagnostics. The company’s OvaSuiteSM platform combines its Ova1Plus and OvaWatch blood tests, offering clinicians the only comprehensive portfolio of AI-powered diagnostic solutions designed to assess ovarian cancer risk among the more than 1.2 million American women diagnosed annually with an adnexal mass.
Aspira’s leadership views this partnership as a validation of its updated go-to-market approach, which focuses on technology-enabled, partnership-driven growth strategies to expand patient access and accelerate revenue.
KEY QUOTE:
“I am pleased to announce such a prestigious new client addition on behalf of our team. One of our top priorities has been to transform and improve our go-to-market strategy. We are extremely focused on growing our Ova1Plus and OvaWatch revenues in the most efficient, accelerated way possible. Our partnership with University of Texas Medical Branch at Galveston is an excellent example of how we aim to quickly leverage technology and strategic relationships to reach more patients and positively impact women’s health.”
Mike Buhle, CEO, Aspira Women’s Health
